Skip to main content
Equibles
NUVB logo

NUVB · Nuvation Bio Inc.

Track NUVB — free Ask ALVIS about NUVB
$6.66 +0.22 (+3.42%) At close · Jul 27
Market Cap
$2.24B
Shares
348.20M

Nuvation Bio Inc. Earnings Call Transcripts

Every quarterly earnings call for Nuvation Bio Inc. (NUVB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $3.08M −$53.24M '25 Q1 25-05-28 ▲236.8% $4.83M −$59.01M '25 Q2 25-08-07 ▲1704.7% $13.12M −$55.79M '25 Q3 25-11-03 ▲633.1% $41.87M −$36.59M '25 Q4 26-03-02 LATEST ▲2598.7% $83.23M $5.40M '26 Q1 26-05-04
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-20
2026 RBC Capital Markets Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-13
Bank of America Securities 2026 Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-04
Nuvation Bio Inc. Q1 FY2026 Earnings Call
Confident tone Iptrozy commercial launch and patient dynamics Future guidance and reporting Clinical data, durability and safety profile
Revenue
$83.23M
▲ 2598.7% YoY
Diluted EPS
$0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-11
The Citizens Life Sciences Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-04
TD Cowen 46th Annual Health Care Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-02
Nuvation Bio Inc. Q4 FY2025 Earnings Call
Confident tone IBTROZI Commercial Launch Pipeline Termination (NUV-1511) ROS1 / TRKb Mechanism
Revenue
$41.87M*
▲ 633.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-13
44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-03
Nuvation Bio Inc. Q3 FY2025 Earnings Call
Confident tone IBTROZI U.S. Commercial Launch Efficacy and Durability Data Pipeline and Partnerships
Revenue
$13.12M
▲ 1704.7% YoY
Diluted EPS
$-0.16
Gross margin
74.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Nuvation Bio Inc. Q2 FY2025 Earnings Call
Confident tone Efficacy and safety profile Pipeline and safusitinib (FAFU) Regulatory discussions
Revenue
$4.83M
▲ 236.8% YoY
Diluted EPS
$-0.17
Gross margin
46.7%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-28
Nuvation Bio Inc. Q1 FY2025 Earnings Call
Confident tone Taletrectinib PDUFA and approval Competitive positioning vs. repotrectinib/crizotinib Safusidenib pipeline asset
Revenue
$3.08M
Diluted EPS
$-0.16
Gross margin
32.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts CIK 1811063 CUSIP 67080N101 13F (30d) 31 filings 31 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)